First, Last and Always: Cannabis Innovation Never Ends in Israel -- CFN Media
Dr. David Dalton
@DrDavidDalton1
Foundation has to be solid .
Operations efficient
Closed Distribution complete
Genetics seed to sale
International presence (Euromed)
Supply Chain Management
Research contracts DEA
Last SEC reporting
Seattle, Washington--(Newsfile Corp. - July 25, 2019) - CFN Media Group ("CFN
Media"
, the leading agency and financial media network dedicated to the North
American cannabis industry announces publication of an article discussing
EuroMed Therapeutics.
When the word "cannabis" is heard, "Israel" probably isn't one of the first
things that jumps to mind. But, for investors it should be. For that matter,
so should EuroMed Therapeutics, an upstart heading toward the public domain.
Here's why.
Top Notch R&D, Perfect Weather and Locale
First, simply consider the overall startup picture and the fact that the tiny
country of about 8 million people has become globally recognized as a tech
innovation hub, startup nation and accelerator. OurCrowd founder and CEO Jon
Medved estimated that $6.5 billion went into Israeli startups in 2018 when
telling Bloomberg to expect more Israeli unicorns coming down the pipeline.
Now consider Israel's pioneering place in the cannabis space. In the 1960's,
the Godfather of cannabis medicine, Dr. Raphael Mechoulam, was the first to
isolate, analyze and synthesize cannabinoids in cannabis. Dr. Mechoulam began
his lifetime of cannabis work at Israel's Weizmann Institute before moving on
to the Hebrew University of Jerusalem.
Unique Opportunity with EuroMed
Balsam Technologies formerly was RewardStream
EuroMed, who is joining the public markets through a reverse merger with
RewardStream Solutions Inc., is a holder of one of only nine cultivation
licenses for export in Israel. It bears repeating that EuroMed has a maximum
of eight competitors as things currently stand. Compare that to Canada (likely
a country that springs to mind upon hearing the word cannabis), which has
issued about 165 licenses.
Accredited? Click here to receive an investor presentation and corporate
updates
EuroMed is a ground floor opportunity. Literally. Working with the greenhouse
engineering and construction experts at Eisenberg Agri Company (Israel)
Limited, the company is laying down the foundation for a 100,000 square foot,
modular-design greenhouse located 45 minutes outside of Jerusalem, with
expectations for completion during the fourth quarter. Phase 1 of construction
includes 22,000 square feet of operational greenhouse by the end of Q1 2020
with the cultivation process launched during Q2.
The state-of-the-art design of the greenhouse will allow for the addition of
11,000 square feet greenhouse every 30 days. Other benefits include the
greenhouse being fully customizable to achieve the ideal micro-climate, which
yields up to 20% higher output.
As for costs, start-up expenses are shaved in half compared to conventional
greenhouses, after which operating costs are expected to be only about 5% of
typical buildings.
Low Cost = Big Margin
Add these factors up and the sum is a premium cannabis product produced at
approximately just $0.30 cents per gram. EuroMed says it will leverage
domestic distribution agreements for Israel and that it also plans to export
product to Europe, where retail prices range as high as $18 per gram. The
company is already in discussions for off-take and joint venture distribution
partners to further accelerate penetrating the European markets.
Management expects to harvest 5,500 kilograms of medicinal grade cannabis in
the first 12 months of operations, which will translate to $22.0 million based
on conservative pricing of $4 per gram.
EuroMed isn't flying blind here. The lean, but highly seasoned team, which
includes Dr. David Dalton, former EVP of Rite Aid and current director of
Pennsylvania-licensed cannabis producer and processor AGRiMED, as a director,
has some good comps to base their projections upon. For instance, fellow
Israeli cannabis company InterCure is able to produce 10,000 kilograms
annually on their 54,450 square foot property.
TOODLES
Dr. David Dalton
@DrDavidDalton1
Foundation has to be solid .
Operations efficient
Closed Distribution complete
Genetics seed to sale
International presence (Euromed)
Supply Chain Management
Research contracts DEA
Last SEC reporting
Seattle, Washington--(Newsfile Corp. - July 25, 2019) - CFN Media Group ("CFN
Media"
, the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing
EuroMed Therapeutics.
When the word "cannabis" is heard, "Israel" probably isn't one of the first
things that jumps to mind. But, for investors it should be. For that matter,
so should EuroMed Therapeutics, an upstart heading toward the public domain.
Here's why.
Top Notch R&D, Perfect Weather and Locale
First, simply consider the overall startup picture and the fact that the tiny
country of about 8 million people has become globally recognized as a tech
innovation hub, startup nation and accelerator. OurCrowd founder and CEO Jon
Medved estimated that $6.5 billion went into Israeli startups in 2018 when
telling Bloomberg to expect more Israeli unicorns coming down the pipeline.
Now consider Israel's pioneering place in the cannabis space. In the 1960's,
the Godfather of cannabis medicine, Dr. Raphael Mechoulam, was the first to
isolate, analyze and synthesize cannabinoids in cannabis. Dr. Mechoulam began
his lifetime of cannabis work at Israel's Weizmann Institute before moving on
to the Hebrew University of Jerusalem.
Unique Opportunity with EuroMed
Balsam Technologies formerly was RewardStream
EuroMed, who is joining the public markets through a reverse merger with
RewardStream Solutions Inc., is a holder of one of only nine cultivation
licenses for export in Israel. It bears repeating that EuroMed has a maximum
of eight competitors as things currently stand. Compare that to Canada (likely
a country that springs to mind upon hearing the word cannabis), which has
issued about 165 licenses.
Accredited? Click here to receive an investor presentation and corporate
updates
EuroMed is a ground floor opportunity. Literally. Working with the greenhouse
engineering and construction experts at Eisenberg Agri Company (Israel)
Limited, the company is laying down the foundation for a 100,000 square foot,
modular-design greenhouse located 45 minutes outside of Jerusalem, with
expectations for completion during the fourth quarter. Phase 1 of construction
includes 22,000 square feet of operational greenhouse by the end of Q1 2020
with the cultivation process launched during Q2.
The state-of-the-art design of the greenhouse will allow for the addition of
11,000 square feet greenhouse every 30 days. Other benefits include the
greenhouse being fully customizable to achieve the ideal micro-climate, which
yields up to 20% higher output.
As for costs, start-up expenses are shaved in half compared to conventional
greenhouses, after which operating costs are expected to be only about 5% of
typical buildings.
Low Cost = Big Margin
Add these factors up and the sum is a premium cannabis product produced at
approximately just $0.30 cents per gram. EuroMed says it will leverage
domestic distribution agreements for Israel and that it also plans to export
product to Europe, where retail prices range as high as $18 per gram. The
company is already in discussions for off-take and joint venture distribution
partners to further accelerate penetrating the European markets.
Management expects to harvest 5,500 kilograms of medicinal grade cannabis in
the first 12 months of operations, which will translate to $22.0 million based
on conservative pricing of $4 per gram.
EuroMed isn't flying blind here. The lean, but highly seasoned team, which
includes Dr. David Dalton, former EVP of Rite Aid and current director of
Pennsylvania-licensed cannabis producer and processor AGRiMED, as a director,
has some good comps to base their projections upon. For instance, fellow
Israeli cannabis company InterCure is able to produce 10,000 kilograms
annually on their 54,450 square foot property.
TOODLES
5
